NZ238356A - Increasing the bioavailability of buspirone (an azaspirondecanedione) relative to its major metabolite by oral administration of a buspirone controlled/extended release formulation
- Google Patents
Increasing the bioavailability of buspirone (an azaspirondecanedione) relative to its major metabolite by oral administration of a buspirone controlled/extended release formulation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE8704097Aexternal-prioritypatent/SE8704097D0/en
Application filed by Bristol Myers Squibb CofiledCriticalBristol Myers Squibb Co
Publication of NZ238356ApublicationCriticalpatent/NZ238356A/en
NZ238356A1987-10-221988-10-18Increasing the bioavailability of buspirone (an azaspirondecanedione) relative to its major metabolite by oral administration of a buspirone controlled/extended release formulation
NZ238356A
(en)
Increasing the bioavailability of buspirone (an azaspirondecanedione) relative to its major metabolite by oral administration of a buspirone controlled/extended release formulation
PROCEDURE FOR PREPARING A STABLE CRYSTALLINE DIET OR TRIHYDRATE OF 7BETA - ((Z) -2- (2-AMINOTIAZOL-4-YL) -4-CARBOXYBUT-2-ENOYLAMINO) -3-CEFEM-4-CARBOXYL
Increasing the bioavailability of buspirone (an azaspirondecanedione) relative to its major metabolite by oral administration of a buspirone controlled/extended release formulation